Welcome to our dedicated page for Lipella Pharmaceuticals SEC filings (Ticker: LIPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lipella Pharmaceuticals Inc. (LIPO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. Lipella remains a reporting company under the Securities Exchange Act of 1934 and continues to file current reports, despite its common stock being delisted from The Nasdaq Capital Market and quoted on an OTC market under the symbol “LIPO,” as noted in its Form 8-K and Form 25 filings.
Through this page, investors can review Form 8-K filings that describe material events affecting Lipella. Recent 8-Ks have covered topics such as the Nasdaq Hearings Panel’s decision to delist the company’s common stock, the suspension of trading on Nasdaq, subsequent quotation on an OTC market, and a stockholder letter addressing the delisting and plans to pursue relisting on a national exchange. Other 8-Ks report on positive Phase 2a results for LP-10 in oral lichen planus, updates to corporate presentations, and planned or actual retirements of members of the board of directors and senior management.
This page also reflects Form 25 (25-NSE) filed by Nasdaq Stock Market LLC to remove Lipella’s common stock from listing and registration under Section 12(b) of the Exchange Act. That filing documents the formal removal of LIPO from The Nasdaq Capital Market and is a key reference for understanding the company’s listing history.
For users analyzing Lipella’s clinical and regulatory trajectory, the company’s SEC reports provide context on its drug reformulation strategy, clinical programs in oral lichen planus and other mucosal disorders, and its ongoing status as an emerging growth company. On Stock Titan, these filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain the significance of complex documents such as 8-Ks and Form 25 notices, highlighting items like clinical trial outcomes, listing changes, and governance developments.
Investors can use this page to monitor Lipella’s periodic and current reporting, track key events affecting LIPO shares, and review disclosures that complement the company’s press releases and scientific communications.
Lipella Pharmaceuticals Inc. has filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania. The company plans to pursue a Section 363 sale process intended to maximize value for creditors.
Lipella expects to seek customary first-day relief so it can continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits in the ordinary course. The company also cautions that trading in its common stock during the Chapter 11 cases is highly speculative and that trading prices may bear little or no relationship to any ultimate recovery for shareholders.
Lipella Pharmaceuticals Inc. reported that board member Dr. Lori A. Birder resigned from its Board of Directors, effective immediately on February 3, 2026. The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, indicating a routine governance change rather than a dispute-driven departure.
Lipella Pharmaceuticals (LIPO) filed its Q3 2025 10-Q, reporting continued operating losses and liquidity pressure. The company posted a Q3 net loss of $1,254,078 on $0 revenue as NIH grant funding ended. Operating expenses were $1,274,272 (R&D $720,973; G&A $553,299), and interest income was $20,194.
Nine‑month results show a net loss of $3,888,087 on $216,117 grant revenue, with operating cash outflow of $3,785,321. Cash and cash equivalents were $1,855,771 and working capital $1,436,889 as of September 30, 2025. Management states these funds may not cover obligations for one year, raising substantial doubt about going concern. The company raised $3,456,228 net via preferred stock/warrants year‑to‑date.
Lipella’s common stock was suspended from Nasdaq on June 20, 2025 and is quoted on OTC; a Form 25‑NSE to delist was filed October 6, 2025. Shares outstanding were 4,620,837 as of November 13, 2025. Program updates note LP‑310 Phase 2a completed with results announced September 18, 2025, while R&D spend shifted from stock‑based comp to outsourced services and salaries.
Lipella Pharmaceuticals Inc. announced a planned board change. On October 20, 2025, Dr. Naoki Yoshimura notified the company of his intention to retire from the Board of Directors, effective December 31, 2025.
The company stated that Dr. Yoshimura’s decision to retire did not result from any disagreement with the company on matters related to operations, policies, or practices.
Lipella Pharmaceuticals Inc. announced that Dr. Michael ChancellorOctober 3, 2025, with the retirement to be effective on December 4, 2025. The company states that Dr. Chancellor’s decision to retire did not result from any disagreement regarding its operations, policies, or practices, indicating an orderly leadership transition rather than a dispute-driven departure.
Lipella Pharmaceuticals, Inc. submitted a Form 25 notification indicating that a class of its securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC.
Nasdaq certifies it has reasonable grounds to file the Form 25 and indicates compliance with the applicable Exchange rules and with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The filing supplies issuer contact details in Pittsburgh but does not disclose timing, reason, or financial effects of the removal.
Lipella Pharmaceuticals Inc. reported positive final results from a completed Phase 2a multicenter, dose‑ranging study of LP-10, a proprietary liposomal tacrolimus oral rinse, in adults with symptomatic oral lichen planus (OLP). The study met its primary safety endpoint and showed statistically significant improvements across all efficacy measures at the 4‑week timepoint in all three dose groups (0.25 mg, 0.5 mg, and 1.0 mg).
The trial enrolled 27 adults with biopsy‑confirmed symptomatic OLP at five U.S. sites; 81.5% were female, the median age was 62 years, disease duration ranged from 1 to 28 years, and all had failed standard therapies such as topical corticosteroids. All patients completed the 4‑week treatment, no serious adverse events were reported, systemic exposure was minimal with 76% of tacrolimus blood measurements below 1.0 ng/mL, and treatment‑related side effects were mild to moderate, mainly dry mouth in 18.5% of patients.
Investigator assessments showed clear reductions in ulceration and erythema, pain and sensitivity improved significantly on numerical rating scales, and patient‑reported symptoms on the OLP Symptom Severity Measure improved, with benefits sustained through a two‑week follow‑up. The company states these results support LP‑10’s potential to become the first FDA‑approved therapy for OLP, which affects an estimated 6 million Americans, and is preparing Phase 2b development, manufacturing scale‑up, and potential strategic partnerships.
Lipella Pharmaceuticals (LIPO) filed an 8-K announcing its delisting from the Nasdaq Capital Market. The company released a stockholder letter from CEO Jonathan Kaufman addressing the delisting and outlining plans to relist on a national exchange. The filing includes a press release and stockholder letter as exhibits 99.1 and 99.2.
As an emerging growth company, Lipella provided standard forward-looking statements cautioning that actual outcomes may differ from expectations regarding product candidate development and relisting efforts.
Lipella Pharmaceuticals Inc. ("LIPO") has been formally delisted from the Nasdaq Capital Market. On 20 June 2025 the company received a Nasdaq Hearings Panel letter, dated 17 June 2025, exercising discretionary authority under Listing Rule 5100 to delist the company’s common stock. The Panel cited two rule violations that arose from private placements conducted between December 2024 and March 2025: (i) failure to secure prior shareholder approval for issuances exceeding 20 % of outstanding shares below the minimum price (Rule 5635(d)), and (ii) actions that disparately reduced or restricted existing shareholders’ voting rights (Rule 5640).
Trading in LIPO shares was suspended at the market open on 20 June 2025. The company expects to file Form 25 with the SEC to formally remove its listing. As of the suspension date, the common stock now trades on the OTC Markets Group’s Pink Market under the existing ticker "LIPO".
The 8-K also furnishes a press release (Exhibit 99.1) announcing the delisting. Management emphasises that forward-looking statements in the filing involve significant risk and that the company is evaluating all market alternatives for future listing; however, no concrete remediation plan or timeline is provided.